Marksans Pharma Ltd

About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.

Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]

Key Points

Revenue Mix [1]
Around 30% comes from Pain Management, 18% comes from Anti-Diabetic, 15% comes from Cardiovascular System(CVS), 13% comes from Cough & Cold, and the rest comes from Gastrointestinal, Central Nervous System(CNS), etc.

See full details
  • Market Cap 2,706 Cr.
  • Current Price 66.1
  • High / Low 97.6 / 48.0
  • Stock P/E 25.7
  • Book Value 14.6
  • Dividend Yield 0.38 %
  • ROCE 22.9 %
  • ROE 17.8 %
  • Face Value 1.00

Pros

  • Company is almost debt free.
  • Debtor days have improved from 126.24 to 89.36 days.

Cons

  • Company has a low return on equity of 12.07% for last 3 years.
  • Earnings include an other income of Rs.45.05 Cr.
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
115 125 91 92 101 117 114 156 138 168 138 147
97 108 88 82 88 97 95 127 115 134 111 122
Operating Profit 18 17 3 10 13 20 18 29 23 35 27 25
OPM % 16% 14% 4% 11% 13% 17% 16% 19% 17% 21% 19% 17%
Other Income 3 0 10 2 8 0 -0 0 13 6 12 14
Interest 2 1 2 2 2 1 2 1 1 1 2 1
Depreciation 2 2 2 3 3 3 3 3 4 4 4 4
Profit before tax 17 14 9 8 16 16 13 25 31 36 32 34
Tax % 25% 16% 36% 28% 24% 19% 44% 11% 24% 19% 27% 15%
Net Profit 12 12 6 6 12 13 7 22 24 29 24 29
EPS in Rs 0.30 0.29 0.14 0.14 0.29 0.32 0.18 0.54 0.57 0.71 0.58 0.71

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 TTM
200 155 155 192 315 406 358 216 295 424 433 600 591
176 235 272 148 231 290 254 191 266 361 362 486 481
Operating Profit 24 -81 -118 44 84 116 104 24 29 63 71 114 110
OPM % 12% -52% -76% 23% 27% 29% 29% 11% 10% 15% 16% 19% 19%
Other Income 1 -79 2 4 3 3 9 7 7 8 0 31 45
Interest 15 39 49 10 15 13 6 4 8 7 7 5 5
Depreciation 10 15 18 9 9 9 15 15 12 9 12 15 16
Profit before tax 1 -213 -183 30 63 97 92 12 17 56 53 124 134
Tax % 54% -2% 1% -34% 12% 31% 22% 3% 25% 22% 28% 21%
Net Profit 0 -218 -181 40 56 67 71 12 12 44 38 98 105
EPS in Rs 1.03 1.44 1.64 1.75 0.28 0.30 1.07 0.93 2.40 2.57
Dividend Payout % 0% 0% 0% 0% 7% 7% 7% 18% 16% 5% 11% 10%
Compounded Sales Growth
10 Years: 15%
5 Years: 11%
3 Years: 27%
TTM: 21%
Compounded Profit Growth
10 Years: 10%
5 Years: 7%
3 Years: 99%
TTM: 94%
Stock Price CAGR
10 Years: 41%
5 Years: 5%
3 Years: 35%
1 Year: 27%
Return on Equity
10 Years: %
5 Years: 9%
3 Years: 12%
Last Year: 18%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
50 50 50 52 52 53 53 41 41 41 41 41
Reserves 125 -92 -240 58 108 305 369 378 388 430 465 559
Borrowings 353 103 100 91 89 50 41 73 67 78 11 14
60 359 345 123 141 132 83 54 61 64 83 104
Total Liabilities 575 407 243 310 376 527 534 546 557 612 600 719
294 185 77 73 67 90 97 94 88 103 115 129
CWIP 0 0 0 0 0 0 0 0 0 0 0 0
Investments 78 68 24 68 68 68 231 234 236 236 236 236
204 154 142 170 242 369 205 217 233 273 249 353
Total Assets 575 407 243 310 376 527 534 546 557 612 600 719

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
12 -68 -61 9 54 112 65 -14 16 20 108 107
-34 26 41 -48 -2 -29 -177 -8 -8 -20 -24 9
42 36 11 22 -19 51 -52 21 -10 1 -82 -14
Net Cash Flow 20 -6 -9 -17 33 134 -164 -1 -2 1 2 102

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Debtor Days 123 170 175 174 130 112 136 262 209 153 136 89
Inventory Days 207 136 167 182 120 85 90 95 91 109 111 101
Days Payable 88 102 123 106 87 75 64 67 73 58 84 69
Cash Conversion Cycle 242 204 220 250 163 123 161 290 228 204 163 121
Working Capital Days 248 -487 -465 115 95 74 133 300 232 193 147 94
ROCE % 3% -32% 71% 35% 33% 22% 3% 5% 12% 11% 23%

Shareholding Pattern

Numbers in percentages

Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25
3.59 3.45 3.18 2.46 2.44 2.54 3.28 4.69 5.05 4.34 3.14 2.64
0.50 0.62 0.51 0.66 0.64 0.89 0.67 0.30 0.30 0.34 0.56 0.53
47.66 47.68 48.06 48.64 48.67 48.32 47.80 46.76 46.40 47.07 48.05 48.58

Documents